Icm Neuro 01: Parkinson's

Front 1

3 criteria for PD
you need ___ to diagnose

Back 1

rest tremor
cogwheel rigidity
bradykinesia
2

Front 2

___ (2) gait and ___graphia are characteristic of PD

Back 2

stooped
shuffling
micro

Front 3

striatum is made of ___ (2)

Back 3

caudate
putamen

Front 4

basal ganglia is made of ___ (3)

Back 4

striatum
globus pallidus
subthalamic nucleus

Front 5

lentiform nucleus is made of ___ (2)

Back 5

putamen
globus pallidus

Front 6

3 brain regions affected in PD

Back 6

basal ganglia
substantia nigra pars compacta
intralaminar nuclei of thalamus

Front 7

___% of DAergic SN cells nee to be lost before patient presents with PD

Back 7

60--70

Front 8

___ is the histopath hallmark of PD. it is mostly made of ___.

Back 8

Lewy body
alpha synuclein

Front 9

Braak (2003) reported that PD first affects ___ (2)

Back 9

olfactory tract
medulla

Front 10

PD presents in the ___th (2) decade. prevalence of PD over 65 is ___%.
PD is more common in men/women

Back 10

6th
7th
1
men

Front 11

when PD occurs before age 50 it's probably ___.

Back 11

genetic

Front 12

PD is associated with ___.

Back 12

Gaucher's

Front 13

___ is a fruit associated with PD. it contains ___ which kills ___s.

Back 13

annona
annonacin
SN cells

Front 14

___ is a neurotoxic heroine derivative which can cause PD

Back 14

MPTP

Front 15

Wilson's disease is a ___ trait. it is treated with ___ (4)

Back 15

AR
reduction of Cu intake
D-penicillamine
Zn
liver transplant

Front 16

if PD symptoms are ___ (2) from the beginning, disease is probably not idiopathic

Back 16

symmetric
not responsive to LDOPA

Front 17

L-DOPA is given with ___ or ___, which are ___s

Back 17

carbidopa
benserazide
DOPA decarboxylase inhibitor

Front 18

___ (2) inhibitors and ___ antagonists are given for PD

Back 18

COMT
MAO-B
NMDAR

Front 19

___ agonists and anti-___ drugs are given for PD

Back 19

DA
cholinergic

Front 20

L-DOPA side effects

Back 20

nausea
vomiting
sinus tachycardia
hypotension

Front 21

4 risk factors for PD motor complications

Back 21

young age at onset
long disease duration
severe disease
high L-DOPA dosage

Front 22

3 peripheral causes of motor complications

Back 22

gastric emptying
dietary protein
short plasma t1/2

Front 23

COMT converts L-DOPA to ___. it is inhibited by ___.

Back 23

3-OMD
entacapone

Front 24

___ combines L-DOPA with DDCI and COMTI

Back 24

stalevo

Front 25

___s directly stimulate the striatum and should be given before L-DOPA. ___ is one.

Back 25

DA agonists
ropinirole

Front 26

5 DA agonist side effects

Back 26

nausea
hallucination
postural hypotension
edema
impulse control

Front 27

2 MAOB inhibitors

Back 27

rasagiline
selegiline

Front 28

rasagiline was found to ___ and not act simply as ___. this means it does/doesn't matter if tx is started earlier

Back 28

modify disease progression
symptomatic tx
does

Front 29

MAO-BI inhibitor side effects

Back 29

postural hypotension
hallucination
confusion

Front 30

4 effects of amantidine in PD

Back 30

releases DA from neurons
inhibits DA reuptake
blocks NMDAR
anticholinergic effect

Front 31

3 side effects of amantidine

Back 31

hallucination
leg edema
livedo reticulcaris

Front 32

T/F: postural instability is an early manifestation of PD

Back 32

false